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ABSTRACT
Introduction A worldwide lack of consensus exists on 
the optimal management of asymptomatic congenital 
pulmonary airway malformation (CPAM) even though 
the incidence is increasing. Either a surgical resection 
is performed or a wait- and- see policy is employed, 
depending on the treating physician. Management is 
largely based on expert opinion and scientific evidence 
is scarce. Wide variations in outcome measures are 
seen between studies making comparison difficult thus 
highlighting the lack of universal consensus in outcome 
measures as well. We aim to define a core outcome set 
which will include the most important core outcome 
parameters for paediatric patients with an asymptomatic 
CPAM.
Methods and analysis This study will include a critical 
appraisal of the current literature followed by a three- 
stage Delphi process with two stakeholder groups. One 
surgical group including paediatric as well as thoracic 
surgeons, and a non- surgeon group including paediatric 
pulmonologists, intensive care and neonatal specialists. 
All participants will score outcome parameters according 
to their level of importance and the most important 
parameters will be determined by consensus.
Ethics and dissemination Electronic informed consent 
will be obtained from all participants. Ethical approval is 
not required. After the core outcome set has been defined, 
we intend to design an international randomised controlled 
trial: the COllaborative Neonatal NEtwork for the first CPAM 
Trial, which will be aimed at determining the optimal 
management of patients with asymptomatic CPAM.
INTRODUCTION
Congenital pulmonary airway malforma-
tion (CPAM), formerly known as congenital 
cystic adenomatoid malformation, is the most 
common congenital lung abnormality.1 The 
incidence of CPAM has increased up to 4 per 
10 000 births over the last years.2 Most infants 
born with a CPAM are asymptomatic but 
others may show symptoms such as neonatal 
respiratory distress, persistent cough or 
recurrent lung infections in the first years 
of life.3 A worldwide lack of consensus exists 
on the optimal management and follow- up 
of infants with an asymptomatic CPAM.4 5 
Prospective studies on postnatal management 
are lacking, and cohort studies vary widely in 
the outcome measures they report.2 6
Strength and limitations of this study
 ► The core outcome set is a disease- specific collec-
tion of the most important outcomes that will be es-
tablished by consensus between key stakeholders.
Participants will be an international group of special-
ists with experience in the treatment of patients with 
congenital pulmonary airway malformation (CPAM), 
which will result in a universally approved synthesis 
of expert opinion.
 ► This protocol describes an international online 
Delphi survey that should identify the most import-
ant core outcome parameters including optimal tim-
ing and modality to monitor paediatric patients with 
an asymptomatic CPAM.
 ► Existing comprehensive literature reviews shall be 
used to inform initial outcome parameters instead 
of a systematic literature search as no randomised 
trials and very few prospective studies have yet 
been published regarding the outcome of patients 
with CPAM.
 ► Parents’ and patients’ views are not included in the 
protocol as the final core outcome set is specifical-
ly intended for patients with asymptomatic CPAM, 
however their input will play an important role when 
designing future studies.
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An asymptomatic CPAM is either surgically resected or 
a wait- and- see policy is employed depending on physi-
cian preference or local guidelines. Either way, cases are 
ideally discussed in a multidisciplinary team in which 
parental preferences are taken into account as well. To 
date, no definitive evidence exists on the optimal manage-
ment, long- term outcomes are still unknown and factors 
for predicting symptoms are still being investigated.6 The 
arguments for a wait- and- see policy are that the malfor-
mation is originally benign, potentially regresses and in 
most cases remains asymptomatic.7 The arguments for 
surgical management include the risk of recurrent lung 
infections (which could make subsequent surgery more 
difficult), risk of acute respiratory distress, potential 
malignant transformation, parental anxiety and allowing 
for compensatory lung growth.8 9
Consensus needs to be reached on outcome measures 
and their timing that can be applied in international 
studies aimed at identifying the optimal management 
of asymptomatic CPAM. A core outcome set (COS) is a 
disease- specific collection of outcomes that have been 
identified by consensus between key stakeholders as 
being the most important in determining success of a 
treatment.10 Such consensus is often reached through a 
Delphi method in which stakeholders anonymously rate 
outcome measures according to their importance, in 
one or multiple rounds.11 We aim to develop a COS for 
patients with CPAM using the Delphi method as a tool 
for reaching consensus and present the study protocol for 
this.
METHODS
The COS development will follow the Core Outcome Set- 
STAndards for Development
Recommendations12 and the Core Outcome Measures 
in Effectiveness Trials (COMET) handbook.11 This COS 
development study was registered with the COMET 
Initiative in May 2020 (http://www. comet- initiative. org/ 
studies/ details/ 1570).
Scope
This protocol describes the Delphi method which shall 
define a COS for all asymptomatic patients who are either 
prenatally or postnatally diagnosed with a CPAM. Asymp-
tomatic patients are defined as those who have no need 
for prolonged respiratory support (>24 hours) including 
supplemental oxygen and ventilation. The COS will 
include the most important outcome measures for 
patients with CPAM, regardless of the management. The 
COS may be used as a guideline for clinical follow- up or in 
future research studies. After the COS has been defined, 
we intend to design a randomised controlled trial: the 
COllaborative Neonatal NEtwork for the first European 
CPAM Trial (CONNECT). This trial will be performed 
by the CONNECT study consortium and aims to iden-
tify the optimal management of patients with asymptom-
atic CPAM. The COS is intended for paediatric patients 
up until the age of 18 years and will not include fetal 
outcome. Outcome parameters as well as their measure-
ment instruments, and age at assessment will be included.
Study design
The COS will be developed in an online, three- round, 
Delphi process, preceded by an appraisal of previously 
published literature.
Literature review
A systematic literature review is recommended to yield 
an initial outcome set for the first round in the Delphi 
process.11 To date, no randomised studies have yet been 
done and other studies examining the management of 
asymptomatic CPAMs report a large variety in outcome 
parameters.6 A literature review will be done by the study 
management coordinators (SH, CK) informed by two 
literature reviews, previously published in a special issue 
of a paediatric surgery scientific journal, each covering 
opposing thoughts on the arguments for surgical manage-
ment8 or a wait- and- see policy.7 In addition, we will scru-
tinise a recent systematic review and meta- analysis, which 
covers the risks associated with either surgical resection 
or a wait- and- see policy of asymptomatic CPAM.3 Existing 
definitions, measurement tools and common measure-
ment time- points for outcomes will be extracted, and 
formatted into appropriately phrased questions for use 
in the first round of the Delphi process. The indepen-
dent coordinators will be blinded for participant identity 
during the process by means of a unique identification 
number and will ensure the Delphi process is performed 
according to the protocol.
Stakeholders and recruitment
Paediatric surgeons and thoracic surgeons are the health-
care professionals who are most frequently involved in 
the operative management of patients with CPAM. Initial 
consultation or follow- up is variably done by paediatric 
surgeons, maternal- fetal medicine specialists, neonatol-
ogists, paediatricians or paediatric pulmonologists. We 
therefore decided to form two stakeholder groups: (1) 
surgeons (ie, paediatric and thoracic surgeons) and 
(2) non- surgeons (eg, maternal- fetal medicine special-
ists, paediatricians, paediatric pulmonologists and 
neonatologists).
We will recruit study participants through an existing 
international network of paediatric surgeons and pulmo-
nologists who have expressed interest in collaborating on 
the CONNECT trial. We will inform potential participants 
on the aims and procedures of the Delphi process and 
encourage them to enrol other specialists involved in the 
care of patients with CPAM in their own centres. Prior 
to the first round, those who have been found willing to 
participate will be sent an email explaining the aims and 
procedures of the Delphi process, and emphasising the 
importance of finishing each round within the allocated 
time.
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Sample size
There is no consensus on the optimal sample size for a 
Delphi study11; recruitment will therefore be based on 
the prospective study for which it is primarily intended 
(CONNECT). For the CONNECT trial, we aim to include 
at least 12 international centres, and therefore set the 
minimum of participants in each stakeholder group in 
the final round at 12. To reduce bias, no more than two 
participants from a single centre can participate in a 
stakeholder group. To minimise attrition bias in consec-
utive rounds, we aim to achieve that 75% of participants 
complete a round.11 13 Therefore, the minimum number 
of participants in each stakeholder group for round 1 will 
be 21, and 16 for round 2. We believe that these minimum 
numbers constitute a representative sample, consid-
ering the rarity of the disease and the limited number of 
professionals with experience in managing this disease. 
Previous Delphi COS studies in paediatric surgery used 
similar numbers for investigating a more common disease 
such as appendicitis.14 15
Attrition bias
Attrition bias will be assessed separately for each round 
of the Delphi process, and separately in each stakeholder 
group. In each group, the median score of every outcome 
will be compared using the Wilcoxon rank- sum test, 
between those only completing the previous round and 
those completing the consecutive round as well.11
Delphi study
Consensus
Participants will be asked to score each outcome param-
eter using the Grading of Recommendations, Assessment, 
Development and Evaluations scale.16 The 9- point Likert 
scale will label 1–3 as ‘not important’, 4–6 as ‘important 
but not critical’ and 7–9 as ‘critical’. Consensus for inclu-
sion is reached if ≥70% of participants rate the outcome 
parameter 7–9 and <15% rate it 1–3. Consensus for exclu-
sion is reached if >70% participants rate the outcome 1–3 
and <15% rate it 7–9. Outcomes not meeting these defi-
nitions will be classified as ‘no consensus’.11
Timeline
Participants will be asked to complete each round of 
the Delphi process within 4 weeks. A weekly reminder 
email will be sent to those who have not yet completed 
the survey. Those failing to complete the questionnaire 
within the allocated 4 weeks will be excluded from next 
rounds. The deadline shall be extended if the projected 
minimum sample size has not been reached and those 
failing to complete the questionnaire shall be approached 
individually.
Delphi round 1
The three- round Delphi process shall be performed 
using ‘Welphi’, an online data system specifically devel-
oped for this use.17 All participants shall be approached 
simultaneously and asked to rate each of the previously 
identified outcome parameters on importance as follows: 
“How important would you rate the following outcome parameter 
including measurement instrument and age in determining the 
best management of asymptomatic CPAM patients?”
Participants are invited to suggest additional outcome 
parameters stating: (1) the outcome parameter, (2) the 
measurement instrument and (3) the age at assessment. 
These additional outcome parameters will be scored in 
the second round.
Delphi round 1 analysis
Outcome parameters will be analysed separately for each 
stakeholder group (surgeons and non- surgeons) and all 
parameters will be included in the second round of the 
Delphi process. The additional outcomes provided by 
participants will be reviewed to confirm they represent 
new outcomes. If confirmed, the item in question will be 
included in the second round as well.
Delphi round 2
All participants who completed the first round will auto-
matically be invited to participate in round 2.
Per stakeholder group, the median scores assigned in 
the first round will be made known. This will allow partic-
ipants to consider the views of the other participants in 
the stakeholder group. They will be invited to look at 
all items again and consider adjusting their own scores. 
Furthermore, they will be asked to score the newly added 
outcome parameters suggested in the first round.
Delphi round 2 analysis
All outcome parameters meeting consensus criteria for 
exclusion by all participants will be excluded from the 
third round. All other parameters will be included in the 
third round.
Delphi round 3
All participants who completed the first and second 
rounds will be invited to participate in the third round. 
The median score of their own stakeholder group and the 
score of the other stakeholder group will be presented to 
participants. This will allow participants to consider the 
views of the other stakeholder group before rescoring the 
outcomes. They will be invited to look at all remaining 
items again and consider adjusting their own scores. In 
addition, participants will be asked to identify a single 
outcome parameter, which is the most important for 
determining the treatment choice in patients with asymp-
tomatic CPAM according to them.
Delphi round 3 analysis and final COS development
All outcome parameters meeting the criteria for consensus 
of inclusion by all participants will be included in the final 
COS. All other outcome parameters will be excluded. To 
achieve a COS that is feasible for clinical use in trials, we 
aim to include a maximum of 10 outcome parameters 
in the final COS. If the number of outcome parameters 
meeting the criteria for consensus of inclusion greatly 
exceeds this maximum number, we will only include the 
10 outcomes with the highest level of consensus for the 
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COS and report those excluded in this stage. The level 
of consensus will be determined by the median score of 
each outcome parameter in round 3.
The final COS will be a collection of the most important 
outcome parameters in patients with CPAM. The final 
COS will be annotated according to the outcome 
taxonomy, which was constructed to maximise future 
data harmonisation. Additionally, the final COS will be 
divided into the four core areas of the OMERACT filter: 
death, life impact, pathophysiological manifestations and 
resource use.10
Ethics and dissemination
Electronic informed consent will be obtained from all 
participants. Prior ethical approval for the Delphi study 
is not required. The final COS will be published in an 
international peer- reviewed scientific journal and on the 
COMET Initiative website (https://www. comet- initiative. 
org/).
Data collection and confidentiality
Participants will complete questionnaires using the 
‘Welphi’ survey tool.17 Anonymised data will be stored on 
a secure online server and will be managed according to 
the European General Data Protection Regulation.18
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